Clinigen Group plc – Half Year Results
Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or ‘the Group’), the global pharmaceuticals and services group, has today published its half year results for the six months ended 31 December 2019.
Read More
Clinigen Group plc – Half Year Trading Update
Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, today provides an unaudited trading update for the six months ended 31 December 2019.
Six AIM overseas earners boosted by weaker pound
Sterling has been weak since Boris Johnson became Prime Minister, but it was also languishing before that. Smaller companies tend to be viewed as dependent on the UK economy, and that is true of some AIM stocks, but there are plenty of examples of AIM companies that have thriving international businesses.
Clinigen Group PLC – Year end trading update
Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, is pleased to announce positive data from its pharmacokinetic (“PK”) study FM58 of MED2002, the Company’s topical gel for erectile dysfunction (“ED”). MED2002 contains glyceryl trinitrate (“GTN”) as its active ingredient.
Clinigen Group plc – US commercial rights of Ethyol® and Totect®
Clinigen Group plc (AIM: CLIN), the global pharmaceutical and services company and Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX, ‘Cumberland’), a US specialty pharmaceutical company, have mutually agreed to transition the marketing, promotion, and distribution of Ethyol® and Totect® in the US to Clinigen from Cumberland.
Clinigen Group plc – US Proleukin rights acquisition
Clinigen Group plc (AIM: CLIN), the global pharmaceutical and services company, has completed the acquisition of the US rights to Proleukin® (aldesleukin, human recombinant interleukin-2), following US anti-trust clearance.
Clinigen Group plc – Half Year Results
Clinigen Group plc (AIM: CLIN), the global pharmaceuticals and services group, has today published its half year results for the six months ended 31 December 2018.
Clinigen Group plc – Half Year trading update
Clinigen Group plc (AIM: CLIN), the global pharmaceutical and services company, today provides an unaudited trading update for the six months ended 31 December 2018.
Clinigen Group plc – Clinigen acquires iQone Healthcare Holding
Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, has agreed to acquire iQone Healthcare Holding (‘iQone’), a privately owned Swiss based speciality pharmaceutical business for an initial consideration of €7.5 million (£6.7 million) on a cash free, debt free basis.
Clinigen Group plc – Year end trading update
Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, today provides an unaudited trading update for the year ended 30 June 2018.